EMERYVILLE, Calif.--(BUSINESS WIRE)--KineMed, Inc. (www.kinemed.com) announced today that David Fineman, KineMed’s Chairman and Chief Executive Officer, will present at the 17th Annual BIO CEO & Investor Conference on Monday, February 9th at 9:15 AM EST, in the Park South Room of the Waldorf Astoria New York. A webcast of the presentation will be available one hour after Mr. Fineman’s presentation at the following URL: http://www.veracast.com/webcasts/bio/ceoinvestor2015/83105386665.cfm
Mr. Fineman’s presentation, entitled “Capturing Value by De-risking and Advancing Therapeutics,” will present applications of KineMed’s kinetic biomarker technology to de-risk and advance Phase 2 clinical programs by (1) rapidly detecting target engagement of therapeutics, and (2) tracking disease progression across a broad spectrum of diseases. “By capturing the underlying biology of disease, KineMed rapidly establishes proof of concept in man, optimizes trial design, and predicts clinical outcome to help enable the era of personalized medicine,” said Mr. Fineman.
About KineMed, Inc.
KineMed is a life sciences company that has developed a platform technology with broad applications in drug development and patient care. Using its patented technology, KineMed has developed analytic biomarker tests that measure, in a single sample, the rate of change of critical biological pathways fundamental to processes of disease and health. KineMed has the unique ability to measure the production and destruction of key molecules involved in health and disease-modifying biological processes. This platform provides meaningful, and previously unavailable, information transformative to healthcare decisions. For more information about KineMed, please visit: www.kinemed.com.